Neuroscience · us
Increasing Healthy Gene Expression: CRISPR Activation Improves Autism-Related Brain-Cell Abnormalities
When one copy of a gene loses function, can the other make up the shortfall? A UCLA team has found preliminary evidence in human neurons and brain organoids, but delivery to the brain and the timing of intervention remain key challenges on the path toward treatment.
Some autism-related gene variants cause problems through insufficient function: one of the two gene copies stops working, while the other continues to function normally but cannot produce enough to meet the cell’s needs. A team at the University of California, Los Angeles (UCLA) tried increasing expression of the healthy copy, improving some developmental and electrical-signaling abnormalities in human brain-cell models and offering a new research direction for this type of genetic mechanism.
Published in *Nature Neuroscience*, the study focused on two autism-related genes, CHD8 and SCN2A. The former is involved in gene regulation needed for brain development, while the latter is essential for neurons to generate electrical signals. The researchers used excitatory neurons derived from human stem cells and organoids that model parts of early cerebral cortex development to test whether increasing expression could compensate when a single normal copy is insufficient to maintain function.
The CRISPR activation technique used by the team does not cut or rewrite DNA. Instead, it brings transcriptional coactivators near “enhancers.” These DNA regulatory regions help determine when and in which cells genes are expressed. According to the research team, targeting enhancers was intended to use cells’ existing regulatory mechanisms to increase gene output while reducing the risk of excessive expression.
In models with CHD8 mutations, intervention reduced abnormal organoid overgrowth, while cell maturation and gene expression also shifted toward a typical state. Neurons deficient in SCN2A recovered a substantial portion of their electrical activity; however, some more subtle electrophysiological properties improved only in certain cell lines, suggesting that different genetic backgrounds may affect the response.
Another finding concerned the selectivity of the effect: within the scope of testing in this study, target gene expression increased only in cells carrying mutations. Healthy control cells did not show the same change, and the neighboring genes tested were unaffected. This is an encouraging preliminary signal, but it is not sufficient to establish long-term safety or rule out other effects that were not measured.
The findings currently come entirely from laboratory models. Improvements in cell growth and electrical firing cannot be directly translated into changes in human cognition, behavior, or daily functioning. The timing of intervention will also influence outcomes: how much benefit increased gene expression might provide after early developmental stages have passed remains to be tested. How to deliver these tools safely to the appropriate cells in the brain also remains unresolved.
The Geschwind laboratory said it is collaborating with the University of California, Davis and Children’s Hospital of Philadelphia to extend the research to mouse models. This approach depends on the presence of a healthy gene copy that can still function, so it cannot be generalized to all autism-related variants. The current findings support a concept worth further testing: in specific cases of insufficient gene function, adjusting the output of an existing gene may offer a chance to alter some cellular abnormalities.